- Home
- LSBK vs SLS Comparison
LSBK vs SLS Comparison
Compare LSBK & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- SLS
- Stock Information
- Founded
- LSBK 1891
- SLS 2012
- Country
- LSBK United States
- SLS United States
- Employees
- LSBK N/A
- SLS N/A
- Industry
- LSBK Savings Institutions
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- LSBK Finance
- SLS Health Care
- Exchange
- LSBK Nasdaq
- SLS Nasdaq
- Market Cap
- LSBK 78.8M
- SLS 70.1M
- IPO Year
- LSBK 2006
- SLS N/A
- Fundamental
- Price
- LSBK $13.73
- SLS $1.06
- Analyst Decision
- LSBK
- SLS
- Analyst Count
- LSBK 0
- SLS 0
- Target Price
- LSBK N/A
- SLS N/A
- AVG Volume (30 Days)
- LSBK 908.0
- SLS 1.4M
- Earning Date
- LSBK 01-29-2025
- SLS 11-13-2024
- Dividend Yield
- LSBK 5.24%
- SLS N/A
- EPS Growth
- LSBK N/A
- SLS N/A
- EPS
- LSBK 0.74
- SLS N/A
- Revenue
- LSBK $25,338,000.00
- SLS N/A
- Revenue This Year
- LSBK N/A
- SLS N/A
- Revenue Next Year
- LSBK N/A
- SLS N/A
- P/E Ratio
- LSBK $18.50
- SLS N/A
- Revenue Growth
- LSBK N/A
- SLS N/A
- 52 Week Low
- LSBK $13.73
- SLS $0.50
- 52 Week High
- LSBK $14.21
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- LSBK 58.03
- SLS 55.79
- Support Level
- LSBK $13.22
- SLS $0.87
- Resistance Level
- LSBK $13.51
- SLS $1.01
- Average True Range (ATR)
- LSBK 0.07
- SLS 0.08
- MACD
- LSBK 0.04
- SLS 0.01
- Stochastic Oscillator
- LSBK 69.23
- SLS 73.08
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.